RenovoRx, Inc. (RNXT): Price and Financial Metrics


RenovoRx, Inc. (RNXT): $2.63

0.02 (+0.77%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add RNXT to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

RNXT Stock Price Chart Interactive Chart >

Price chart for RNXT

RNXT Price/Volume Stats

Current price $2.63 52-week high $5.00
Prev. close $2.61 52-week low $1.50
Day low $2.57 Volume 9,733
Day high $2.68 Avg. volume 67,557
50-day MA $2.36 Dividend yield N/A
200-day MA $2.10 Market Cap 23.86M

RenovoRx, Inc. (RNXT) Company Bio


RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of solid tumors. Its lead product candidate is RenovoGem, a drug and device combination consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. The company was founded in 2009 and is headquartered in Los Altos, California.


RNXT Latest News Stream


Event/Time News Detail
Loading, please wait...

RNXT Latest Social Stream


Loading social stream, please wait...

View Full RNXT Social Stream

Latest RNXT News From Around the Web

Below are the latest news stories about RENOVORX INC that investors may wish to consider to help them evaluate RNXT as an investment opportunity.

RenovoRx to Present at the Sequire Biotechnology Virtual Conference on February 2, 2023

LOS ALTOS, Calif., January 25, 2023--RenovoRx, Inc. (Nasdaq: RNXT), a biopharmaceutical company focused on the localized treatment of solid tumors, today announced that Shaun Bagai, Chief Executive Officer, is scheduled to present virtually at the Sequire Biotechnology Conference on Thursday, February 2, 2023 at 4 p.m. (ET). To register for the event, visit the Sequire Biotechnology Conference website.

Yahoo | January 25, 2023

RenovoRx Reports Initial Results From Targeted Treatment For Pancreatic Cancer

RenovoRx Inc (NASDAQ: RNXT) announced initial results from a pharmacokinetic (PK) substudy within the phase 3 un-blinded randomized control TIGeR-PaC clinical trial to be presented at the 2023 ASCO Gastrointestinal (ASCO GI) Cancers Symposium this week. The TIGeR-PaC clinical trial is evaluating intra-arterial (IA) administration of gemcitabine (chemotherapy) using the proprietary RenovoRx Trans-Arterial Micro-Perfusion (RenovoTAMP) platform for targeted treatment of Locally Advanced Pancreatic

Yahoo | January 18, 2023

RenovoRx Announces Initial Results in Pharmacokinetic (PK) Substudy: Data on RenovoGem™ Supports Potential for RenovoTAMP® Therapy Platform to Increase Local Gemcitabine (Chemotherapy) Delivery and Decrease Side Effects of Pancreatic Cancer Treatment

LOS ALTOS, Calif., January 18, 2023--RenovoRx, Inc. (Nasdaq: RNXT), a biopharmaceutical company focused on the localized treatment of solid tumors, today announced initial results from a pharmacokinetic (PK) substudy within the phase III un-blinded randomized control TIGeR-PaC clinical trial to be presented at the 2023 ASCO Gastrointestinal (ASCO GI) Cancers Symposium this week. The TIGeR-PaC clinical trial is evaluating intra-arterial (IA) administration of gemcitabine (chemotherapy) using the

Yahoo | January 18, 2023

Here's Why RenovoRx (NASDAQ:RNXT) Must Use Its Cash Wisely

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...

Yahoo | January 11, 2023

RenovoRx Strengthens Intellectual Property (IP) Portfolio with Eighth US Patent

LOS ALTOS, Calif., January 05, 2023--RenovoRx, Inc. (Nasdaq: RNXT), a biopharmaceutical company focused on the localized treatment of difficult-to-treat solid tumors, today announced that on January 3, 2023 the United States Patent and Trademark Office issued US patent number 11,541,211 broadly covering methods for treating cholangiocarcinoma (bile duct cancer) by selectively delivering one or more therapeutic agents into targeted regions of the bile duct. This is RenovoRx’s eighth US patent.

Yahoo | January 5, 2023

Read More 'RNXT' Stories Here

RNXT Price Returns

1-mo 11.91%
3-mo 49.43%
6-mo 35.57%
1-year -20.78%
3-year N/A
5-year N/A
YTD 11.91%
2022 -51.45%
2021 N/A
2020 N/A
2019 N/A
2018 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.5418 seconds.